The Economic Times  Jun 18  Comment 
Mumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin’s recently-filed biosimilar Etanercept in Japan.
FiercePharma  Jun 15  Comment 
Novartis’ Sandoz is looking to biosimilars to help it out of an industrywide generics slump. And to spur greater uptake of those drugs, it has new data supporting switching patients from branded products.
Yahoo  Jun 6  Comment 
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
Motley Fool  Jun 5  Comment 
Mylan's latest FDA approval puts it in direct competition against one of Amgen's most important drugs.
MarketWatch  Jun 5  Comment 
The company scored the first U.S. approval of a biosimilar Neulasta late Monday, a lucrative product that has brought in billions in sales.


Amgen, the world’s first big biotech company (and, for a while, the largest), rode to prominence thanks to its drugs for treating anemia – a condition caused by the destruction of red blood cells, often as a result of cancer, cancer treatment, or kidney disease. In FY 2010, the company generated revenues of $15B with net earnings of $4.6B.[1]

Studies in 2007 found that patients taking Amgen’s drugs for anemia caused by cancer were more likely to die than patients who do not take these drugs; the drugs may have increased the migration rate or the rate of metastasis of the tumor. Since then, these drugs have been used less frequently and at lower doses in some therapeutic areas – particularly oncology, where Medicare's decision to restrict reimbursement as a result of safety issues has had a large impact on sales. These changes in prescription frequency have had a major effect on Amgen's revenues.[2]

Corporate Overview

Amgen generally sells its drugs directly to doctors and hospitals, who distribute them to patients and then bill payors for reimbursement. In most cases, the payor is the federal government via Medicare. As a result, Amgen is locked in a constant struggle with the government to ensure its drugs are paid for and at a high enough rate that doctors can use them profitably. Because of its focus on nephrology patients – who automatically qualify for Medicare – the percentage of Amgen’s revenues that are ultimately paid for by the federal government is higher than any other major pharmaceutical company. To secure its interests, Amgen has one of the strongest lobbying presences in Washington, D.C. of any pharmaceutical company.

Recent News

On Jan 24, 2011, Amgen announced the acquisition of BioVex, a privately held biotechnology company, for up to $1 billion. BioVex is testing a cancer therapy (currently in Phase III), OncoVex, which is a virus that kills tumors and stimulates the immune system to fight melanoma, head and neck cancer. [3]

Business Segments

Amgen is a biotechnology company who primarily markets recombinant protein therapeutic products for nephrology, supportive cancer care, and immunology.


Epogen ($2.52B in 2010)

EPOGEN® is Amgen’s original blockbuster drug, and the engine of much of the company’s sales.[4] It is used to treat kidney dialysis patients for anemia. It's patent protection is set to expire in 2013.[5]

Aranesp ($2.52B in 2010)

Aranesp is a longer-acting version of Epogen. It is mostly used outside of dialysis -- for patients in the earlier stages of kidney disease, with cancer, or for several other conditions.[4] Unlike Epogen, Aranesp does not have a monopoly in its markets. In the early years of the company, Amgen licensed the right to sell EPOGEN outside of dialysis to Johnson & Johnson (JNJ), which sells it under the brand name PROCRIT. Johnson & Johnson has since become Amgen's biggest competitor in this area. Procrit is identical to Epogen and is manufactured by Amgen.

Aranesp's revenue has steadily fallen since 2007, when studies in oncology patients found that patients taking Aranesp had shorter survival times than those who were not on the drug. These studied led to dramatic decreases in the use of the drug for cancer-related anemia.

Sensipar ($714M in 2010)

Launched in 2004, Sensipar's is Amgen's first small-molecule drug. It is used to treat secondary hyperparathyroidism, a mineral metabolism complication common in dialysis patients. Sensipar competes most directly with Abbott Laboratories (ABT)'s Zemplar and Genzyme (GENZ)'s Hectorol.


Until recently, Amgen's oncology drugs were exclusively supportive care products. Aranesp, Neupogen, and Neulasta treat complications that arise from chemotherapy; they do not treat the cancer itself. This strategy has proved lucrative for Amgen. While "therapeutics" -- the term for drugs that treat cancer directly -- are usually only used for a subset of cancers, Amgen's products are used as part of therapy for multiple types of cancer. As a result, Amgen has one of the largest exposures to the oncology market of any pharmaceutical company. In recent years however, Amgen has put enormous resources into its oncology therapeutics pipeline, in an attempt to develop drugs that directly treat cancer itself rather than side-effects from cancer treatment. Therapeutics are seen as more essential to cancer care; as such, they command higher prices and there is less pressure from payors (such as insurance companies and the federal government) to reduce their reimbursement.

Neupogen & Neulasta ($4.84B combined revenue in 2010)

Neupogen and neulasta both treat a condition called neutropenia -- a weakening of the immune system as a result of chemotherapy. Patients on high-dose chemotherapy sometimes develop infections that can be life-threatening due to their inability to fight off germs. Neulasta boosts patients' immune systems, decreasing the risk of infections and allowing them to tolerate higher doses of chemotherapy. Neulasta is a longer-acting version of Neupogen, requiring less-frequent injections. Neulasta is also significantly more expensive than Neupogen, and more profitable for Amgen as a result.



Enbrel, which was acquired with Amgen's buyout of Immunex in 2003, is used to treat Rheumatoid Arthritis (see Arthritis drug market), Psoriasis, and a number of other rheumatological conditions. Enbrel is a low margin product for Amgen; it's expensive to make and the cost of making it eats up a much greater portion of sales than for Amgen's other drugs. In addition, profits are split with Pfizer (PFE), which owns half the rights to Enbrel since its purchase of Wyeth.[4]

Trends and Forces

Generic Drug Competition for Biologics

Biologic drugs are much harder to replicate than small molecule drugs, and current legislation makes it very difficult for competitors to produce generic versions of the drug. However, proposed new legislation may pave a pathway for generic biologics, which if approved will affect the arthritis market by enabling the entry of generic competition which will lower prices and decrease the overall market size.[6] Such legislation already exists in the European Union.[7] Generic biologics are more expensive to manufacture than their small-molecule counterparts, and will likely sell at a higher price. In addition, there will be a higher barrier to entry as manufacturing expertise and clinical proof are required at higher levels. As such, Amgen is well positioned to maintain its market share, since it is relatively protected against generic competition, unlike more traditional pharmaceutical companies.

National Coverage Decision

On July 30, 2007, the Centers for Medicare and Medicaid Services (CMS) announced a National Coverage Decision (NCD) which affects the reimbursement policies of many of Amgen's anemia drugs, in particular Aranesp. In order to qualify for reimbursement under the new policy, chemotherapy patients must have hemoglobin levels below 10 grams per decileter. Amgen estimates that most patients taking its anemia drugs do not meet this criteria, so as a result of this new policy, fewer patients will be treated with its drugs. As of now, no health insurance policies have completely adopted the NCD, but may do so in the near future. Amgen has submitted an appeal to the CMS to reconsider the NCD, increasing the hemoglobin target to cover more patients. The outcome of the NCD is especially important for the company because the majority of product sales are related to anemia and oncology. Amgen routinely spends more money on lobbying annually than any other pharmaceutical/biotech company.[8]

Tightening FDA Regulations

I am making this up <--- REALLY?

Beginning in 2009, the FDA implemented a series of reforms that include stricter monitoring of drug adverse events, more funding for the agency, stronger ability to force product recalls, more scientific expertise within the agency, more transparency. While the tightened regulations and increased transparency will eventually improve the overall quality of pharmaceutical products, companies will have to adjust to the stricter standards and stronger enforcement.[9]


In the Arenesp's anemia market, Amgen's major competitor is Johnson & Johnson, which sells the anemia drug Procrit. Amgen's Enbrel, which competes in the arthritis drug market, competes with Abbott Labs' Humira, Johnson & Johnson's Remicade, and Pfizer's Celebrex. Secondary hyperparathyroid medication Sensipar competes most directly with Abbott Laboratories (ABT)'s Zemplar and Genzyme (GENZ)'s Hectorol. Epogen operates as a relative monopoly, and Neupogen and Neulasta do not have direct competitors.

Competition in the pharmaceutical industry lies mostly in specific drug markets. For example, a new diabetes drug is not going to have any effect on an existing cholesterol drug, no matter how successful it is. As a result, financial data on the pharmaceutical companies do not tell the whole story. Instead, it may be more appropriate to analyze Amgen's competitors by each drug market (See section on Major Drugs and Industry Trends).

  • JOHNSON & JOHNSON (JNJ) - Johnson & Johnson is a large pharmaceutical and consumer products company, whose anemia drug, Procrit, is a major competitor of Amgen's Arenesp. The company's arthritis drug, Remicade, competes with Amgen's Enbrel.
  • Pfizer (PFE) - Pfizer is the largest pharmaceutical company in the world; they currently split the revenus of Enbrel with Amgen. The company's arthritis drug, Celebrex, competes with Amgen's Enbrel.
  • Novartis AG (NVS) - Novartis is a large diversified pharmaceutical company that competes with Amgen.
  • Abbott Laboratories (ABT) - Abbott Laboratories is a large diversified pharmaceutical company that competes with Amgen. The company's arthritis drug, Humira, competes with Amgen's Enbrel. The company's hyperparathyroid drug, Zemplar, competes with Amgen's Sensipar.
  • Merck (MRK) - Merck is a large diversified pharmaceutical company that competes with Amgen.
  • Bristol-Myers Squibb Company (BMY) - Bristol-Myers Squibb is a large diversified pharmaceutical company that competes with Amgen.
  • Eli Lilly and Company (LLY) - Eli Lilly is a large diversified pharmaceutical company that competes with Amgen.
  • Gilead Sciences (GILD) - Gilead Sciences is a large diversified pharmaceutical company that competes with Amgen.
  • AstraZeneca (AZN) - AstraZeneca is a large diversified pharmaceutical company that competes with Amgen.
  • Roche Pharmaceuticals (RHHBY) - Roche Pharmaceuticals is a large diversified pharmaceutical company that competes with Amgen.
  • Genzyme (GENZ) - Genzyme is a large diversified pharmaceutical company that competes with amgen. The company's hyperparathyroid drug, Hectorol, competes with Amgen's Sensipar.


  1. AMGN 2010 10-K, Item 6: Selected Financial Data, p. 65
  2. Amgen Q4 Results
  3. Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
  4. 4.0 4.1 4.2 Amgen 10K 2010
  5. A Biotech Wonder Grows Up, Forbes, 9/3/01
  6. BIO: Biosimilars, Follow-On Biologics
  7. [www.eahp.eu/content/download/25698/168176/file/SSR36-37.pdf Biogeneric drugs: from promise to reality in Europe].
  8. Pharmaceuticals/Health Products Lobbying Database 2010
  9. The FDA: A tough tonic
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki